Compare Abeona Therapeutics Inc (ABEO) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Symbotic Inc — how do they compare? Abeona Therapeutics Inc trades at $6.66 (market cap $373.32M), while Symbotic Inc trades at $40.15 (market cap $5.26B). The key difference: Symbotic Inc is far larger — about 14.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SYM | |
|---|---|---|
Market Cap | $373.32M | $5.26B |
Sector | Health | Technology |
52-Week High | $7.23 | $87.30 |
52-Week Low | $4.17 | $38.57 |
Enterprise Value | $228.22M | $3.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SYM trades at $44.46, up 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $2.25B in 2025. Recent news highlights the acquisition of ARMS Innovations, expanding its warehouse automation solutions, amid high investor interest in robotics stocks.
The outlook is cautiously optimistic with a consensus price target of $57.50, but risks include negative net income margins and high valuation multiples like EV/EBITDA of 246.96. Upside potential hinges on execution in the growing automation market, while downside risks involve competitive pressures and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
